Edgewise Therapeutics, Inc. (EWTX) Free cash flow 2020–2025
Edgewise Therapeutics, Inc. (EWTX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$144.1MFY2025 · since FY2020: -$14.8M → -$144.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$144.1M | -30.6% |
| FY2024 | -$110.3M | -12.9% |
| FY2023 | -$97.7M | -67.9% |
| FY2022 | -$58.2M | -70.2% |
| FY2021 | -$34.2M | -130.3% |
| FY2020 | -$14.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More EWTX financial trends
EWTX RevenueEWTX Net incomeEWTX Net marginEWTX Gross profitEWTX Gross marginEWTX Operating incomeEWTX Operating marginEWTX Operating cash flowEWTX Capital expendituresEWTX Return on equityEWTX Stock buybacksEWTX Dividends paidEWTX Total assetsEWTX Total liabilitiesEWTX Shareholders’ equityEWTX overview →